The atypical cannabinoid O-1602 increases hind paw sensitisation in the chronic constriction injury model of neuropathic pain

Neuroscience Letters

Volumn 508, Issue 2, 2012, Pages 119-122

  Breen, Courtney ^a   Brownjohn, Philip W ^a   Ashton, John C ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Allodynia; Chronic constriction injury; GPR55; Neuropathic pain; O 1602; Von Frey hair

Indexed keywords

CANNABINOID DERIVATIVE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 55; O 1602; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC CONSTRICTION INJURY; CONTROLLED STUDY; DESENSITIZATION; DISEASE MODEL; HIND PAW SENSITIZATION; MALE; NERVE INJURY; NERVE SURGERY; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RAT; SENSITIZATION;

ANIMALS; CANNABINOIDS; CONSTRICTION; CYCLOHEXANES; HINDLIMB; HYPERALGESIA; MALE; MODELS, ANIMAL; NEURALGIA; RATS; RATS, WISTAR; RESORCINOLS;

EID: 84856085948     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.12.039     Document Type: Article

References (26)

1. Bennett G.J., Xie Y.K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988, 33:87-107.
2. Diaz-Arteaga A., Vazquez M.J., Vazquez-Martinez R., Pulido M.R., Suarez J., Velasquez D.A., Lopez M., Ross R.A., de Fonseca F.R., Bermudez-Silva F.J., Malagon M.M., Dieguez C., Nogueiras R. The atypical cannabinoid O-1602 stimulates food intake and adiposity in rats. Diabetes Obes. Metab. 2011.
3. Dixon W.J. Efficient analysis of experimental observations. Annu. Rev. Pharmacol. Toxicol. 1980, 20:441-462.
4. Johns D.G., Behm D.J., Walker D.J., Ao Z., Shapland E.M., Daniels D.A., Riddick M., Dowell S., Staton P.C., Green P., Shabon U., Bao W., Aiyar N., Yue T.L., Brown A.J., Morrison A.D., Douglas S.A. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br. J. Pharmacol. 2007, 152:825-831.
5. Lauckner J., Jensen J., Chen H., Lu H., Hille B., Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:2699.
6. Lauckner J.E., Jensen J.B., Chen H.Y., Lu H.C., Hille B., Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:2699-2704.
7. McHugh D., Hu S.S.J., Rimmerman N., Juknat A., Vogel Z., Walker J.M., Bradshaw H.B. N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci. 2010, 11:44.
8. Milligan E.D., Mehmert K.K., Hinde J.L., Harvey L.O., Martin D., Tracey K.J., Maier S.F., Watkins L.R. Thermal hyperalgesia and mechanical allodynia produced by intrathecal administration of the human immunodeficiency virus-1 (HIV-1) envelope glycoprotein, gp120. Brain Res. 2000, 861:105-116.
9. Mogil J.S., Marek P., Yirmiya R., Balian H., Sadowski B., Taylor A.N., Liebeskind J.C. Antagonism of the non-opioid component of ethanol-induced analgesia by the NMDA receptor antagonist MK-801. Brain Res. 1993, 602:126-130.
10. Neumann S., Doubell T., Leslie T., Woolf C. Inflammatory pain hypersensitivity mediated by phenotypic switch in myelinated primary sensory neurons. Nature 1996.
11. Nevalainen T., Irving A.J. GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity?. Curr. Top. Med. Chem. 2010, 10:799-813.
12. Oka S., Nakajima K., Yamashita A., Kishimoto S., Sugiura T. Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem. Biophys. Res. Commun. 2007, 362:928-934.
13. Oka S., Toshida T., Maruyama K., Nakajima K., Yamashita A., Sugiura T. 2-Arachidonoyl-sn-glycero-3-phosphoinositol: a possible natural ligand for GPR55. J. Biochem. 2009, 145:13-20.
14. Owolabi S.A., Saab C.Y. Fractalkine and minocycline alter neuronal activity in the spinal cord dorsal horn. FEBS Lett. 2006, 580:4306-4310.
15. Pietr M., Kozela E., Levy R., Rimmerman N., Lin Y., Stella N., Vogel Z., Juknat A. Differential changes in GPR55 during microglial cell activation. FEBS Lett. 2009, 583:2071-2076.
16. Pietr M., Kozela E., Levy R., Rimmerman N., Lin Y.H., Stella N., Vogel Z., Juknat A. Differential changes in GPR55 during microglial cell activation. FEBS Lett. 2009, 583:2071-2076.
17. Romero-Zerbo S.Y., Rafacho A., Diaz-Arteaga A., Suarez J., Quesada I., Imbernon M., Ross R.A., Dieguez C., Rodriguez de Fonseca F., Nogueiras R., Nadal A., Bermudez-Silva F.J. A role for the putative cannabinoid receptor GPR55 in the islets of Langerhans. J. Endocrinol. 2011, 211:177-185.
18. Ross R. The enigmatic pharmacology of GPR55. Trends Pharmacol. Sci. 2009, 30:156-163.
19. Ryberg E., Larsson N., Sjogren S., Hjorth S., Hermansson N.O., Leonova J., Elebring T., Nilsson K., Drmota T., Greasley P.J. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 2007, 152:1092-1101.
20. Schicho R., Bashashati M., Bawa M., McHugh D., Saur D., Hu H.M., Zimmer A., Lutz B., Mackie K., Bradshaw H.B., McCafferty D.M., Sharkey K.A., Storr M. The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. Inflamm. Bowel Dis. 2011, 17:1651-1664.
21. Schuelert N., McDougall J.J. The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55. Neurosci. Lett. 2011, 500:72-76.
22. Staton P.C., Hatcher J.P., Walker D.J., Morrison A.D., Shapland E.M., Hughes J.P., Chong E., Mander P.K., Green P.J., Billinton A., Fulleylove M., Lancaster H.C., Smith J.C., Bailey L.T., Wise A., Brown A.J., Richardson J.C., Chessell I.P. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 2008, 139:225-236.
23. Stewart L.S., Martin W.J. Influence of postoperative analgesics on the development of neuropathic pain in rats. Comp. Med. 2003, 53:29-36.
24. Valenzano K.J., Tafesse L., Lee G., Harrison J.E., Boulet J.M., Gottshall S.L., Mark L., Pearson M.S., Miller W., Shan S., Rabadi L., Rotshteyn Y., Chaffer S.M., Turchin P.I., Elsemore D.A., Toth M., Koetzner L., Whiteside G.T. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 2005, 48:658-672.
25. 2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression. J. Cell Sci. 2008, 121:1704-1717.
26. Watkins L., Milligan E., Maier S. Glial activation: a driving force for pathological pain. Trends Neurosci. 2001, 24:450-455.